ATE74512T1 - Pharmazeutische zusammensetzungen von rekombinanten interleukin-2 und herstellungsverfahren. - Google Patents
Pharmazeutische zusammensetzungen von rekombinanten interleukin-2 und herstellungsverfahren.Info
- Publication number
- ATE74512T1 ATE74512T1 AT87115694T AT87115694T ATE74512T1 AT E74512 T1 ATE74512 T1 AT E74512T1 AT 87115694 T AT87115694 T AT 87115694T AT 87115694 T AT87115694 T AT 87115694T AT E74512 T1 ATE74512 T1 AT E74512T1
- Authority
- AT
- Austria
- Prior art keywords
- pharmaceutical compositions
- recombinant interleukin
- manufacture
- solubilizer
- stabilizers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92338386A | 1986-10-27 | 1986-10-27 | |
EP87115694A EP0268110B1 (de) | 1986-10-27 | 1987-10-26 | Pharmazeutische Zusammensetzungen von rekombinanten Interleukin-2 und Herstellungsverfahren |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE74512T1 true ATE74512T1 (de) | 1992-04-15 |
Family
ID=25448603
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT87115694T ATE74512T1 (de) | 1986-10-27 | 1987-10-26 | Pharmazeutische zusammensetzungen von rekombinanten interleukin-2 und herstellungsverfahren. |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0268110B1 (de) |
JP (1) | JPS63122628A (de) |
AT (1) | ATE74512T1 (de) |
AU (1) | AU614066B2 (de) |
CA (1) | CA1292686C (de) |
DE (1) | DE3778122D1 (de) |
ES (1) | ES2036558T3 (de) |
GR (1) | GR3004479T3 (de) |
IE (1) | IE60890B1 (de) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5037644A (en) * | 1986-10-27 | 1991-08-06 | Cetus Corporation | Pharmaceutical compositions of recombinant interleukin-2 and formulation processes |
US4931543A (en) * | 1987-05-11 | 1990-06-05 | Cetus Corporation | Process for recovering microbially produced interleukin-2 |
US6060459A (en) * | 1987-10-28 | 2000-05-09 | Pro-Neuron, Inc. | Enhancing blood cell count with oxypurine nucleosides |
ES2054099T3 (es) * | 1988-12-06 | 1994-08-01 | Otsuka Pharma Co Ltd | Composicion estabilizada de interleucina-1-g(b). |
US6586222B1 (en) | 1989-08-16 | 2003-07-01 | Chiron Corporation | Recombinant PR-3 and compositions thereof |
US5998378A (en) * | 1989-08-16 | 1999-12-07 | Chiron Corporation | Compositions for the inhibition of TNF hormone formation and uses thereof |
US5843693A (en) * | 1989-08-16 | 1998-12-01 | Chiron Corporation | Assay method for screening for inhibitors of proTNF conversion |
JPH0791318B2 (ja) * | 1989-09-21 | 1995-10-04 | 三井東圧化学株式会社 | 蛋白質水溶液、蛋白質水溶液の濃度増大方法および蛋白質製剤 |
US5830452A (en) * | 1990-11-20 | 1998-11-03 | Chiron Corporation | Method for enhancing the anti-tumor therapeutic index of interleukin-2 |
US6063764A (en) * | 1992-06-01 | 2000-05-16 | Washington University & Chiron Corp. | Method for using lipoprotein associated coagulation inhibitor to treat sepsis |
US20030171292A1 (en) | 1992-06-01 | 2003-09-11 | Creasey Abla A. | Method for using lipoprotein associated coagulation inhibitor to treat sepsis |
ATE198277T1 (de) * | 1992-10-02 | 2001-01-15 | Genetics Inst | Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator |
JPH09505721A (ja) * | 1992-10-20 | 1997-06-10 | シータス オンコロジー コーポレイション | インターロイキン6レセプターアンタゴニスト |
SE9301581D0 (sv) * | 1993-05-07 | 1993-05-07 | Kabi Pharmacia Ab | Protein formulation |
US6288030B1 (en) | 1993-12-22 | 2001-09-11 | Amgen Inc. | Stem cell factor formulations and methods |
PL374506A1 (en) | 2001-10-15 | 2005-10-31 | Chiron Corporation | Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi) |
SI1682180T1 (sl) | 2003-11-04 | 2010-03-31 | Novartis Vaccines & Diagnostic | Antagonist anti cd monoklonskih antiteles in postopek za njihovo uporabo |
CA2544368C (en) | 2003-11-04 | 2014-04-01 | Chiron Corporation | Methods of therapy for b cell-related cancers |
KR101128777B1 (ko) | 2003-11-04 | 2012-04-13 | 조마 테크놀로지 리미티드 | 다발성 골수종을 치료하기 위한 길항제 항-cd40단클론성 항체의 용도 |
ATE476991T1 (de) | 2003-11-04 | 2010-08-15 | Novartis Vaccines & Diagnostic | Verfahren zur behandlung von soliden tumoren mit expression des cd40-zelloberflächen-antigens |
US20070110754A1 (en) | 2003-11-04 | 2007-05-17 | Chiron Corporation | Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia |
GB0404586D0 (en) * | 2004-03-01 | 2004-04-07 | Britannia Pharmaceuticals Ltd | Improvements in or relating to organic materials |
KR100624013B1 (ko) | 2004-06-25 | 2006-09-19 | 주식회사 녹십자홀딩스 | 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제 |
JP5518608B2 (ja) * | 2010-07-09 | 2014-06-11 | ロート製薬株式会社 | 粘膜適用液状組成物 |
AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
WO2012075111A1 (en) | 2010-11-30 | 2012-06-07 | Novartis Ag | Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers |
AU2011335551B2 (en) | 2010-12-02 | 2016-10-06 | Bionor Immuno As | Peptide scaffold design |
CN103347892B (zh) | 2011-01-06 | 2016-11-02 | 比奥诺尔免疫有限公司 | 单体和多聚体免疫原性肽 |
DE102012101864A1 (de) * | 2012-03-06 | 2013-09-12 | Gramme-Revit Gmbh | Mittel zur Behandlung von Allergien und anderen Erkrankungen |
JP6310909B2 (ja) | 2012-06-06 | 2018-04-11 | ビオノール イミュノ エーエスBionor Immuno As | 免疫原及び投薬反応物として使用するためのウイルスタンパク質に由来するペプチド |
UA105278C2 (ru) | 2012-09-06 | 2014-04-25 | Інститут Біології Клітини Нан України | Способ получения каталитически активных антител (абзимов) с сиалидазной активностью |
KR102069723B1 (ko) | 2013-04-23 | 2020-01-23 | 세다르스-신나이 메디칼 센터 | 형광단들로부터의 가시 광 이미지 및 적외선 광 이미지를 동시에 레코딩하기 위한 시스템들 및 방법들 |
EP3791889B1 (de) | 2014-01-17 | 2024-02-21 | Cedars-Sinai Medical Center | Auf den c-met rezeptor abzielende konstrukte und verwendungen davon |
KR102567244B1 (ko) | 2014-06-12 | 2023-08-16 | 세다르스-신나이 메디칼 센터 | 암을 치료하는 조성물 및 방법 |
EP3173074A4 (de) | 2014-07-22 | 2018-03-07 | Lemonex Inc. | Zusammensetzung zur verabreichung von bioaktivem material oder protein und verwendung davon |
WO2016073647A2 (en) | 2014-11-04 | 2016-05-12 | University Of Southern California | COMPOSITIONS AND METHODS FOR TREATING HIF-1alpha OVER-EXPRESSING CANCERS |
US10441644B2 (en) | 2015-05-05 | 2019-10-15 | The Regents Of The University Of California | H3.3 CTL peptides and uses thereof |
WO2016179326A1 (en) | 2015-05-05 | 2016-11-10 | The Regents Of The University Of California | H3.3 ctl peptides and uses thereof |
WO2017040594A1 (en) | 2015-08-31 | 2017-03-09 | Cedars-Sinai Medical Center | Novel blood cell biomarker for late onset alzheimer's disease |
WO2017138924A1 (en) | 2016-02-09 | 2017-08-17 | Autotelic Llc | Compositions and methods for treating pancreatic cancer |
WO2017138925A1 (en) | 2016-02-09 | 2017-08-17 | Autotelic Llc | Antitumour combinations of antisense oligonucleotides and anticancer agents |
WO2018143787A1 (ko) | 2017-02-06 | 2018-08-09 | 주식회사 레모넥스 | 생리활성물질 전달체 |
BR112019016281A2 (pt) | 2017-02-06 | 2020-04-14 | Lemonex Inc | veículo de substância fisiologicamente ativa |
US20210121493A1 (en) | 2017-07-25 | 2021-04-29 | Cedars-Sinai Medical Center | Methods for treating liver diseases |
KR102152348B1 (ko) | 2017-09-05 | 2020-09-08 | 주식회사 레모넥스 | 세포 운명 조절용 조성물 |
JP2022512937A (ja) | 2018-11-08 | 2022-02-07 | セダーズ-シナイ メディカル センター | Hla感作患者を脱感作し患者における腎移植を改善するためのクラザキズマブの使用 |
AU2019404553A1 (en) | 2018-12-20 | 2021-06-24 | Cedars-Sinai Medical Center | Clazakizumab in the treatment of chronic antibody-mediated rejection of organ transplant |
WO2021160887A1 (en) | 2020-02-14 | 2021-08-19 | Immunor As | Corona virus vaccine |
MX2023005458A (es) * | 2020-11-13 | 2023-05-23 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Composicion farmaceutica que comprende una variante de la interleucina humana 2 o un derivado de la misma y uso de la misma. |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2652636A1 (de) * | 1976-11-19 | 1978-05-24 | Hans Uwe Dr Rer Nat Wolf | Verfahren zur stabilisierung von proteinen und verwandten verbindungen waehrend ihrer reinigung, isolierung und lagerung |
US4457916A (en) * | 1982-08-31 | 1984-07-03 | Asahi Kasei Kogyo Kabushiki Kaisha | Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same |
WO1985004328A1 (en) * | 1984-03-28 | 1985-10-10 | Cetus Corporation | Pharmaceutical compositions of microbially produced interleukin-2 |
EP0158487B1 (de) * | 1984-04-09 | 1991-08-28 | Takeda Chemical Industries, Ltd. | Stabile Interleukin-2-Zusammensetzung |
CA1297003C (en) * | 1985-09-20 | 1992-03-10 | Jack H. Nunberg | Composition and method for treating animals |
US4822605A (en) * | 1986-02-18 | 1989-04-18 | Exovir, Inc. | Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like |
-
1987
- 1987-10-16 CA CA000549488A patent/CA1292686C/en not_active Expired - Lifetime
- 1987-10-22 IE IE284487A patent/IE60890B1/en not_active IP Right Cessation
- 1987-10-26 ES ES198787115694T patent/ES2036558T3/es not_active Expired - Lifetime
- 1987-10-26 AT AT87115694T patent/ATE74512T1/de not_active IP Right Cessation
- 1987-10-26 EP EP87115694A patent/EP0268110B1/de not_active Expired - Lifetime
- 1987-10-26 DE DE8787115694T patent/DE3778122D1/de not_active Expired - Lifetime
- 1987-10-27 AU AU80181/87A patent/AU614066B2/en not_active Expired - Fee Related
- 1987-10-27 JP JP62271603A patent/JPS63122628A/ja active Pending
-
1992
- 1992-05-04 GR GR920400417T patent/GR3004479T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
ES2036558T3 (es) | 1993-06-01 |
AU614066B2 (en) | 1991-08-22 |
CA1292686C (en) | 1991-12-03 |
IE872844L (en) | 1988-04-27 |
DE3778122D1 (de) | 1992-05-14 |
IE60890B1 (en) | 1994-08-24 |
JPS63122628A (ja) | 1988-05-26 |
AU8018187A (en) | 1988-04-28 |
GR3004479T3 (de) | 1993-03-31 |
EP0268110B1 (de) | 1992-04-08 |
EP0268110A1 (de) | 1988-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE74512T1 (de) | Pharmazeutische zusammensetzungen von rekombinanten interleukin-2 und herstellungsverfahren. | |
ATE111744T1 (de) | Pharmazeutische zusammensetzungen von rekombinantem beta-interferon und herstellungsverfahren. | |
DK0388220T3 (da) | Præparater til vedvarende frigivelse af klorhexidin | |
ES2132066T3 (es) | Procedimiento para la produccion de proteina biologicamente activa (v.g. tfg). | |
AU590896B2 (en) | Improved formulations for recombinant beta-interferon | |
DK16890D0 (da) | Antiviral eller antibakteriel forbindelse og frem gangsmaade til anvendelse heraf | |
ATE72988T1 (de) | Fettsaeure-zusammensetzungen. | |
DK0693924T3 (da) | Fremgangsmåde til (in vivo)-levering af biologiske materialer og sammensætninger, der er egnede dertil | |
DE3681243D1 (de) | Stabile formulierung biologisch aktiver proteine zur parenteralen injektion. | |
IT1232827B (it) | Proteine biologicamente attive, formulazioni che le contengono e metodo per prepararle ed applicarle | |
SE8404065D0 (sv) | Novel biologically active compounds | |
FR2707638B1 (fr) | Nouveaux dérivés d'amino-acides, leurs procédés de préparation et leur application thérapeutique. | |
DE3783923T3 (de) | Einen Wirkstoff und ein in Wasser quellendes Polymer enthaltendes Arzneimittel. | |
DK291390D0 (da) | Terapeutiske anvendelser af 2',5'-oligoadenylatderivater | |
DK516288A (da) | Stabilisering af terapeutisk aktive proteiner i farmaceutiske praeparater | |
DE69228031T2 (de) | Ch0ndromodulin-II Protein | |
FR2605223B1 (fr) | Compositions therapeutiques stables a base d' huile vegetale hydrophobe et son procede de preparation | |
DE3781017D1 (de) | Cytotoxische zusammensetzung aus "killer"-zellen. | |
IT8622051A1 (it) | Composizioni farmaceutiche ad attivita' cicatrizzante | |
BG60657B2 (en) | Human recombinant interleukin-2 muteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification | ||
EEFA | Change of the company name | ||
EEIH | Change in the person of patent owner | ||
EELA | Cancelled due to lapse of time |